Insider · CIK 0001488864

Duarte Ira

Reports to the SEC for 3 companies · CARY, NC

sec.gov

Transactions

Companies

Filings

CIK

0001488864

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-07-31	HRTXHERON THERAPEUTICS, INC. /DE/ · Restricted Stock UnitsM Exercise/Conversion	EVP, Chief Financial Officer	MExercise/Conversion	−11.7K sh	—	—	116,944
2026-07-31	HRTXHERON THERAPEUTICS, INC. /DE/M Exercise/Conversion	EVP, Chief Financial Officer	MExercise/Conversion	+11.7K sh	—	—	285,225
2026-07-31	HRTXHERON THERAPEUTICS, INC. /DE/F Tax Payment	EVP, Chief Financial Officer	FTax Payment	−3,326 sh	$0.50	−$1,663	281,899
2026-07-30	HRTXHERON THERAPEUTICS, INC. /DE/M Exercise/Conversion	EVP, Chief Financial Officer	MExercise/Conversion	+13.5K sh	—	—	277,381
2026-07-30	HRTXHERON THERAPEUTICS, INC. /DE/F Tax Payment	EVP, Chief Financial Officer	FTax Payment	−3,850 sh	$0.50	−$1,925	273,531
2026-07-30	HRTXHERON THERAPEUTICS, INC. /DE/ · Restricted Stock UnitsM Exercise/Conversion	EVP, Chief Financial Officer	MExercise/Conversion	−13.5K sh	—	—	189,492
2026-07-19	HRTXHERON THERAPEUTICS, INC. /DE/F Tax Payment	EVP, Chief Financial Officer	FTax Payment	−1,101 sh	$0.47	−$517.47	263,846
2026-07-19	HRTXHERON THERAPEUTICS, INC. /DE/ · Restricted Stock UnitsM Exercise/Conversion	EVP, Chief Financial Officer	MExercise/Conversion	−3,874 sh	—	—	23,246
2026-07-19	HRTXHERON THERAPEUTICS, INC. /DE/M Exercise/Conversion	EVP, Chief Financial Officer	MExercise/Conversion	+3,874 sh	—	—	264,947
2026-06-16	HRTXHERON THERAPEUTICS, INC. /DE/M Exercise/Conversion	EVP, Chief Financial Officer	MExercise/Conversion	+12.5K sh	—	—	264,628
2026-06-16	HRTXHERON THERAPEUTICS, INC. /DE/F Tax Payment	EVP, Chief Financial Officer	FTax Payment	−3,555 sh	$0.38	−$1,350.9	261,073
2026-06-16	HRTXHERON THERAPEUTICS, INC. /DE/ · Restricted Stock UnitsM Exercise/Conversion	EVP, Chief Financial Officer	MExercise/Conversion	−12.5K sh	—	—	12,500
2026-04-30	HRTXHERON THERAPEUTICS, INC. /DE/M Exercise/Conversion	EVP, Chief Financial Officer	MExercise/Conversion	+13.5K sh	—	—	252,128
2026-04-30	HRTXHERON THERAPEUTICS, INC. /DE/ · Restricted Stock UnitsM Exercise/Conversion	EVP, Chief Financial Officer	MExercise/Conversion	−13.5K sh	—	—	203,027
2026-04-30	HRTXHERON THERAPEUTICS, INC. /DE/M Exercise/Conversion	EVP, Chief Financial Officer	MExercise/Conversion	+11.7K sh	—	—	227,570
2026-04-30	HRTXHERON THERAPEUTICS, INC. /DE/ · Restricted Stock UnitsM Exercise/Conversion	EVP, Chief Financial Officer	MExercise/Conversion	−11.7K sh	—	—	128,638
2026-04-19	HRTXHERON THERAPEUTICS, INC. /DE/ · Restricted Stock UnitsM Exercise/Conversion	EVP, Chief Financial Officer	MExercise/Conversion	−3,874 sh	—	—	27,120
2026-04-19	HRTXHERON THERAPEUTICS, INC. /DE/M Exercise/Conversion	EVP, Chief Financial Officer	MExercise/Conversion	+3,874 sh	—	—	215,876
2026-01-31	HRTXHERON THERAPEUTICS, INC. /DE/M Exercise/Conversion	EVP, Chief Financial Officer	MExercise/Conversion	+11.7K sh	—	—	195,356
2026-01-31	HRTXHERON THERAPEUTICS, INC. /DE/ · Restricted Stock UnitsM Exercise/Conversion	EVP, Chief Financial Officer	MExercise/Conversion	−11.7K sh	—	—	140,332
2026-01-30	HRTXHERON THERAPEUTICS, INC. /DE/ · Performance Stock UnitsA Award	EVP, Chief Financial Officer	AAward	+217K sh	—	—	216,561
2026-01-30	HRTXHERON THERAPEUTICS, INC. /DE/ · Restricted Stock UnitsA Award	EVP, Chief Financial Officer	AAward	+217K sh	—	—	216,562
2026-01-19	HRTXHERON THERAPEUTICS, INC. /DE/M Exercise/Conversion	EVP, Chief Financial Officer	MExercise/Conversion	+3,875 sh	—	—	183,661
2026-01-19	HRTXHERON THERAPEUTICS, INC. /DE/ · Restricted Stock UnitsM Exercise/Conversion	EVP, Chief Financial Officer	MExercise/Conversion	−3,875 sh	—	—	30,994
2025-10-31	HRTXHERON THERAPEUTICS, INC. /DE/ · Restricted Stock UnitsM Exercise/Conversion	EVP, Chief Financial Officer	MExercise/Conversion	−11.7K sh	—	—	152,027
2025-10-31	HRTXHERON THERAPEUTICS, INC. /DE/M Exercise/Conversion	EVP, Chief Financial Officer	MExercise/Conversion	+11.7K sh	—	—	179,786
2025-10-19	HRTXHERON THERAPEUTICS, INC. /DE/ · Restricted Stock UnitsM Exercise/Conversion	EVP, Chief Financial Officer	MExercise/Conversion	−3,874 sh	—	—	34,869
2025-10-19	HRTXHERON THERAPEUTICS, INC. /DE/M Exercise/Conversion	EVP, Chief Financial Officer	MExercise/Conversion	+3,874 sh	—	—	168,092
2025-07-31	HRTXHERON THERAPEUTICS, INC. /DE/M Exercise/Conversion	EVP, Chief Financial Officer	MExercise/Conversion	+11.7K sh	—	—	164,218
2025-07-31	HRTXHERON THERAPEUTICS, INC. /DE/ · Restricted Stock UnitsM Exercise/Conversion	EVP, Chief Financial Officer	MExercise/Conversion	−11.7K sh	—	—	163,721
2025-07-19	HRTXHERON THERAPEUTICS, INC. /DE/ · Restricted Stock UnitsM Exercise/Conversion	EVP, Chief Financial Officer	MExercise/Conversion	−3,874 sh	—	—	38,743
2025-07-19	HRTXHERON THERAPEUTICS, INC. /DE/M Exercise/Conversion	EVP, Chief Financial Officer	MExercise/Conversion	+3,874 sh	—	—	152,523
2025-06-24	TSNDFTerrAscend Corp.A Award	Director	AAward	+434K sh	—	—	657,930
2025-06-16	HRTXHERON THERAPEUTICS, INC. /DE/M Exercise/Conversion	EVP, Chief Financial Officer	MExercise/Conversion	+12.5K sh	—	—	148,649
2025-06-16	HRTXHERON THERAPEUTICS, INC. /DE/ · Restricted Stock UnitsM Exercise/Conversion	EVP, Chief Financial Officer	MExercise/Conversion	+12.5K sh	—	—	25,000
2025-04-30	HRTXHERON THERAPEUTICS, INC. /DE/M Exercise/Conversion	EVP, Chief Financial Officer	MExercise/Conversion	+11.7K sh	—	—	136,149
2025-04-30	HRTXHERON THERAPEUTICS, INC. /DE/ · Restricted Stock UnitsM Exercise/Conversion	EVP, Chief Financial Officer	MExercise/Conversion	+11.7K sh	—	—	175,416
2025-04-19	HRTXHERON THERAPEUTICS, INC. /DE/ · Restricted Stock UnitsM Exercise/Conversion	EVP, Chief Financial Officer	MExercise/Conversion	+3,875 sh	—	—	42,617
2025-04-19	HRTXHERON THERAPEUTICS, INC. /DE/M Exercise/Conversion	EVP, Chief Financial Officer	MExercise/Conversion	+3,875 sh	—	—	124,455
2025-01-31	HRTXHERON THERAPEUTICS, INC. /DE/ · Employee Stock Option (Right to Buy)A Award	EVP, Chief Financial Officer	AAward	+374K sh	—	—	374,220
2025-01-31	HRTXHERON THERAPEUTICS, INC. /DE/ · Restricted Stock UnitsA Award	EVP, Chief Financial Officer	AAward	+187K sh	—	—	187,110
2025-01-19	HRTXHERON THERAPEUTICS, INC. /DE/M Exercise/Conversion	EVP, Chief Financial Officer	MExercise/Conversion	+3,874 sh	—	—	120,580
2025-01-19	HRTXHERON THERAPEUTICS, INC. /DE/ · Restricted Stock UnitsM Exercise/Conversion	EVP, Chief Financial Officer	MExercise/Conversion	−3,874 sh	—	—	46,492
2024-12-31	TSNDFTerrAscend Corp.F Tax Payment	Director	FTax Payment	−71.7K sh	$0.65	−$46.6K	224,277
2024-10-19	HRTXHERON THERAPEUTICS, INC. /DE/M Exercise/Conversion	EVP, Chief Financial Officer	MExercise/Conversion	+3,874 sh	—	—	108,001
2024-10-19	HRTXHERON THERAPEUTICS, INC. /DE/ · Restricted Stock UnitsM Exercise/Conversion	EVP, Chief Financial Officer	MExercise/Conversion	−3,874 sh	—	—	50,366
2024-07-19	HRTXHERON THERAPEUTICS, INC. /DE/ · Restricted Stock UnitsM Exercise/Conversion	EVP, Chief Financial Officer	MExercise/Conversion	−3,875 sh	—	—	54,240
2024-07-19	HRTXHERON THERAPEUTICS, INC. /DE/M Exercise/Conversion	EVP, Chief Financial Officer	MExercise/Conversion	+3,875 sh	—	—	104,127
2024-06-17	TSNDFTerrAscend Corp.A Award	Director	AAward	+163K sh	—	—	295,981
2024-06-16	HRTXHERON THERAPEUTICS, INC. /DE/ · Restricted Stock UnitsM Exercise/Conversion	EVP, Chief Financial Officer	MExercise/Conversion	−12.5K sh	—	—	37,500

Recent filings

Accepted (ET)
Aug 34
Duarte Ira0001193125-26-329720
SEC(opens sec.gov)
Jul 204
Duarte Ira0001193125-26-308887
SEC(opens sec.gov)
Jun 174
Duarte Ira0001193125-26-273552
SEC(opens sec.gov)
May 44
Duarte Ira0001193125-26-203272
SEC(opens sec.gov)
Apr 214
Duarte Ira0001193125-26-165304
SEC(opens sec.gov)
Feb 34
Duarte Ira0001193125-26-034492
SEC(opens sec.gov)

Companies

Address

25 FENTON MAIN STREET SUITE 300

CARY, NC, 27511